<var id="j1dh7"><strike id="j1dh7"></strike></var><var id="j1dh7"><strike id="j1dh7"><thead id="j1dh7"></thead></strike></var>
<ins id="j1dh7"><span id="j1dh7"><thead id="j1dh7"></thead></span></ins>
<var id="j1dh7"></var>
<cite id="j1dh7"><strike id="j1dh7"><listing id="j1dh7"></listing></strike></cite><cite id="j1dh7"><strike id="j1dh7"><listing id="j1dh7"></listing></strike></cite>
<cite id="j1dh7"><video id="j1dh7"></video></cite>
<var id="j1dh7"></var>
<var id="j1dh7"></var>
<cite id="j1dh7"><span id="j1dh7"><var id="j1dh7"></var></span></cite>
<cite id="j1dh7"></cite><cite id="j1dh7"><span id="j1dh7"></span></cite>

JMD Properties acquires molecular diagnostics firm Stella Diagnostics
Category: #headline  By Mateen Dalal  Date: 2020-09-03
  • share
  • Twitter
  • Facebook
  • LinkedIn

JMD Properties acquires molecular diagnostics firm Stella Diagnostics

JMD Properties, has reportedly announced the acquisition of Stella Diagnostics, LLC, a molecular diagnostics firm aimed at enhancing patient management strategies of more than 67 million people suffering from esophageal diseases. JMD procured Stella under a preferred stock takeover deal and would be changing the company name to Stella Diagnostics, Inc., to better convey the company’s new area of focus.

Chairman of the Board of JMD Properties, Daniel Wainstein stated that the firm is confident that its foray into the biotech industry’s diagnostics sector would be extremely beneficial for both its investors and to patients diagnosed with serious esophageal disease. This disease population is considerably underserved and consistently growing across the U.S. and abroad.

Dr. Joe Abdo, incoming CEO of the company stated that six million Americans suffer from Barrett’s esophagus, which could be a precursor to the deadliest cancer relating to the incidence in the nation. The number of esophageal cancer cases is growing quicker than any other cancer type, showing a tremendous 6-fold growth over the past 20 years.

Dr. Abdo further added that four of the five patients with esophageal cancer meet the oncologist while in advanced stages of cancer growth. This is the major reason why the duration of survival is short after the cancer is diagnosed. Stella Diagnostics’ goal is to stratify patients on the basis of the seriousness of disease with its multi-pronged diagnostic approach. By doing so, critical patients would be identified while the disease is still treatable. The company is thrilled about the new agreement with JMDP that would offer the firm with all resources it needs to make sure that its tests reach providers as well as patients quickly.

Apart from the name change as part of the proposed acquisition, the firm would also change its company symbol. It would file this symbol change action with FINRA soon.

Source credit: https://finance.yahoo.com/news/jmd-properties-inc-acquires-diagnostic-132600876.html

About Author

Mateen Dalal    

Mateen Dalal

Despite working as a professional testing engineer, Mateen Dalal always held a liking for content creation. Following his passion, he now pens down articles for itresearchbrief.com and a couple of similar portals. Mateen is a qualified electronics and telecommunicat...

Read More>>

More News By Mateen Dalal

Biopharma startup Telix begins Phase III prostate cancer therapy trial
Biopharma startup Telix begins Phase III prostate cancer therapy trial
By Mateen Dalal

Telix Pharmaceuticals Ltd., an Australia-based pharmaceutical company, has reportedly received Human...

Health Canada reduces age eligibility of Pfizer’s COVID-19 shot to 12
Health Canada reduces age eligibility of Pfizer’s COVID-19 shot to 12
By Mateen Dalal

Reportedly, Health Canada has authorized the use of COVID-19 vaccine which is manufactured by Pfizer...

Bajaj Healthcare introduces generic Favipiravir for treating COVID-19
Bajaj Healthcare introduces generic Favipiravir for treating COVID-19
By Mateen Dalal

Bajaj Healthcare has successfully produced the API and Favipiravir using its in-house R&D team...


性XXXX欧美老妇胖老太,欧美人禽杂交狂配,亚洲老汉色Av影院在线,日韩AV在线